Financial Data and Key Metrics Changes - Group sales increased slightly by 1% year-on-year in Q3 2024, with growth in Pharmaceuticals and Consumer Health offsetting a decline in Crop Science [15][18] - EBITDA before special items was €1.3 billion, a decrease of 26% or approximately €430 million compared to the prior year [15][16] - Core earnings per share were €0.24, down €0.14 from the previous year, primarily due to lower contributions from EBITDA [16] - Free cash flow for Q3 was €1.1 billion, compared to €1.6 billion in the same quarter last year, with year-to-date free cash flow at minus €200 million [16][17] - Net financial debt was reduced to €35 billion by the end of Q3, aided by positive cash contributions and foreign exchange tailwinds [17] Business Line Data and Key Metrics Changes Crop Science - Sales declined by 4% to approximately €4 billion in Q3, impacted by weather challenges and commodity price softness [18] - EBITDA before special items for Crop Science was €35 million, approximately €60 million above the prior year's quarter [18] Pharmaceuticals - Sales grew by 2% year-on-year to €4.5 billion, driven by strong performance from launch assets like Nubeqa and Kerendia [19] - Xarelto saw a 23% decline in quarterly sales, aligning with guidance of a double-digit sales decline [19] Consumer Health - Achieved 6% year-over-year sales growth in Q3, reaching €1.4 billion, with broad-based growth across categories [20] - Clean EBITDA margin improved to 25.5%, a 330 basis point increase year-over-year [20] Market Data and Key Metrics Changes - The agriculture market is expected to decline around 2% in 2024, with Crop Science facing significant challenges in Latin America [4][21] - Consumer Health is experiencing a slowdown in growth in key markets like the US and China, impacting overall performance [4][21] Company Strategy and Development Direction - The company is focused on operational efficiency and targeted price management to navigate market pressures [23] - There is a commitment to innovation, with plans for significant product launches in the coming years, particularly in Crop Science and Pharmaceuticals [9][35] - The new operating model aims to enhance speed, efficiency, and creativity within the organization [38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year targets for sales growth, core earnings per share, and free cash flow despite headwinds [5][23] - There are concerns about regulatory challenges and generic pricing pressures impacting Crop Science, with a cautious outlook for 2025 [6][21] - The company is committed to addressing litigation issues and maintaining focus on cash conversion and operational performance [11][40] Other Important Information - The company has scaled its new operating model to the majority of the organization, resulting in a reduction of 5,500 jobs, primarily in managerial positions [13] - The company is exploring various avenues to contain litigation risks, particularly related to glyphosate and PCBs [12] Q&A Session Summary Question: Dicamba registration and alternative offerings for farmers - Management discussed the potential impact of not having Dicamba re-registered and outlined plans to offer alternative chemistries to farmers [41][42] Question: Financial outlook for 2025 and operational savings - Management refrained from quantifying EBITDA decline for 2025 but emphasized ongoing efforts to accelerate operational savings [44][45] Question: Xarelto impact clarification - Management clarified that the Xarelto impact is expected to peak in 2026, considering the timeline of genericization [46] Question: Raw material and seed production cost reductions - Management confirmed expectations for lower raw material and seed production costs in 2025, alongside ongoing DSO savings initiatives [48][49]

///////////// Health for all, Hunger for none Q3 2024 Investor Call N o v e m b e r 1 2 , 2 0 2 4 Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. ...

Group 1 - The article discusses the author's long position in shares of BMY, BAYRY, and BASFY, indicating a positive outlook on these companies [1] - It emphasizes the importance of conducting due diligence and research before making any investment decisions, highlighting the risks associated with short-term trading and options trading [2] - The article clarifies that past performance is not indicative of future results and that no specific investment recommendations are provided [3]

KEY TAKEAWAYSBayer shares are falling 11% in German trading after the pharmaceuticals and crop science conglomerate reduced its full-year earnings target amid a tough agricultural market.The Monsanto parent said it now expects 2024 EBITDA before special items of between 10.4 billion euros ($11.05 billion) and 10.7 billion euros ($11.36 billion), down from its previous range of between 10.7 billion euros and 11.3 billion euros.Agricultural companies, including Archer Daniels Midland, have been hit by lower g ...

Bayer (BAYRY) announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency ("EMA") for its pipeline candidate elinzanetant. The MAA is seeking approval of the candidate for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause or adjuvant endocrine therapy. Image Source: Zacks Investment Research Year to date, shares of Bayer have lost 21.7% against the industry's growth of 20.6%. BAYRY's Progress Wit ...

Core Viewpoint - Bayer AG's shares experienced a nearly 7% decline following a U.S. court's decision to review a case related to the harmful effects of its Monsanto unit's products [1][3]. Group 1: Legal Challenges - The Washington Supreme Court has agreed to review litigation concerning the impact of polychlorinated biphenyls (PCBs) exposure at the Sky Valley Education Center in Washington state, which is part of a broader set of legal challenges Bayer is facing [2]. - An appeals court previously overturned a $185 million award in May, citing flaws in the case [2]. - Bayer maintains that there is "no basis for a different outcome on appeal," arguing that the claims are based on industrial materials that Monsanto ceased manufacturing in 1977 [4]. Group 2: Financial Performance - Bayer's shares were down 6.76% at 12:45 p.m. London time, marking the company's worst performance since March and extending a year-to-date loss of 13% [3]. - The company faced a significant decline of over 30% in its shares last year due to ongoing litigation and high net debt [3]. Group 3: Historical Context and Settlements - Bayer acquired Monsanto in 2018, which has led to numerous legal challenges regarding alleged health effects, including cancer, from products like Roundup weed killer [5]. - Approximately 125,000 claims have been filed against Roundup in the U.S., with more than half resolved following a $10.9 billion settlement in 2020 [5]. - In September, Bayer achieved a legal victory when the 3rd U.S. Circuit Court of Appeals ruled in its favor regarding a claim that Monsanto failed to include a cancer warning on the Roundup label [6].

Bayer Ag (BAYRY) and its wholly owned subsidiary BlueRock Therapeutics LP announced positive 24-month data from an early-stage study on experimental candidate bemdaneprocel (BRT-DA01). Bemdaneprocel, an investigational cell therapy, is being evaluated for the treatment of Parkinson's disease. exPDite is a multi-center, multi-site, open-label, non-randomized, non-controlled phase I study. Data from the phase I exPDite study at 24 months continue to show a favorable safety profile in all 12 participants in th ...

MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) CEO Corey Giasson joined Proactive to chat about the company's transition to commercialization from its R&D focus. He noted the commercialization of its biofertility product TerraSante, which has gained momentum in key US states. The CEO also discussed MustGrow's partnership with Bayer, which involves a commercial licensing agreement for their soil biopesticide TerraMG. Proactive: Some news today, talking in essence about what's going on within the company ...

Bayer (BAYRY) announced the submission of a supplemental new drug application (sNDA) to the FDA for darolutamide. The sNDA is seeking approval of darolutamide, in combination with androgen deprivation therapy (ADT), in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the androgen receptor with high affinity and exhibits strong antagonistic activity. It inhibits the receptor function ...

Investors might want to bet on Bayer Aktiengesellschaft (BAYRY) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following yea ...